The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.

The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.

The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.

Provided herein are therapeutic acrylate compounds useful as medical adhesives, comprising a therapeutic agent covalently linked to a methacrylate or cyanoacrylate moiety. Adhesive compositions and kits, such as liquid sutures and bone cement also are provided along with uses for the compositions.

The present disclosure relates to organic electroluminescent materials and organic electroluminescent devices, in particular, discloses a compound of formula (1), wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each independently selected from hydrogen, a substituted or unsubstituted C.sub.1-20 alkyl, a substituted or unsubstituted C.sub.3-20 cycloalkyl, a substituted or unsubstituted aromatic hydrocarbyl, or a substituted or unsubstituted aromatic heterocyclic group; and at least one of R.sub.1, R.sub.2, R.sub.3 and R.sub.4 contains a group having a hole-transporting ability; and at least one of R.sub.1, R.sub.2, R.sub.3 and R.sub.4 contains a group having an electron-transporting ability; A and B each independently represent hydrogen, a substituted or unsubstituted, fused aromatic ring, or a substituted or unsubstituted, fused heteroaromatic ring containing a heteroatom(s) selected from O, N and S. ##STR00001##

The present disclosure relates to organic electroluminescent materials and organic electroluminescent devices, in particular, discloses a compound of formula (1), wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each independently selected from hydrogen, a substituted or unsubstituted C.sub.1-20 alkyl, a substituted or unsubstituted C.sub.3-20 cycloalkyl, a substituted or unsubstituted aromatic hydrocarbyl, or a substituted or unsubstituted aromatic heterocyclic group; and at least one of R.sub.1, R.sub.2, R.sub.3 and R.sub.4 contains a group having a hole-transporting ability; and at least one of R.sub.1, R.sub.2, R.sub.3 and R.sub.4 contains a group having an electron-transporting ability; A and B each independently represent hydrogen, a substituted or unsubstituted, fused aromatic ring, or a substituted or unsubstituted, fused heteroaromatic ring containing a heteroatom(s) selected from O, N and S. ##STR00001##

The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.

The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.

A compound for use as a cross-linking agent represented by the following formula (1) wherein R.sup.1 is SO.sub.2, O, CO, an optionally substituted alkylene group, a group represented by the following formula (2) or a single bond; and two As are each independently an aromatic ring group containing a 5- or 6-membered aromatic ring and optionally containing a substituent, where the aromatic ring group contains a substituent in the case where the aromatic ring group is a monocyclic aromatic ring group containing a 6-membered aromatic hydrocarbon ring. Also disclosed is a composition containing the cross-linking agent.

##STR00001##

A compound for use as a cross-linking agent represented by the following formula (1) wherein R.sup.1 is SO.sub.2, O, CO, an optionally substituted alkylene group, a group represented by the following formula (2) or a single bond; and two As are each independently an aromatic ring group containing a 5- or 6-membered aromatic ring and optionally containing a substituent, where the aromatic ring group contains a substituent in the case where the aromatic ring group is a monocyclic aromatic ring group containing a 6-membered aromatic hydrocarbon ring. Also disclosed is a composition containing the cross-linking agent.

##STR00001##